13Nov 2024
TiNivo-2 Trial Supports Tivozanib Monotherapy for Advanced RCC

TiNivo-2 Trial Supports Tivozanib Monotherapy for Advanced RCC

The multicentre, randomized phase III TiNivo-2 trial assessed the effectiveness of tivozanib monotherapy versus its combination with the immune checkpoint inhibitor nivolumab in patients with advanced renal cell carcinoma (RCC) who had progressed on one or two prior therapies, including one immune checkpoint inhibitor (ICI). Results demonstrated that patients receiving tivozanib alone had a higher progression-free survival (PFS) of 7.4 months compared to 5.7 months for the combination group (HR 1.10, 95% CI 0.84–1.43; P = 0.49). These findings suggest that re-challenging advanced RCC patients with ICI therapy may not be beneficial, positioning tivozanib monotherapy as a viable post-ICI treatment option for managing advanced RCC.

  • #urology

Like

Save

Share